The large phase 3 DETERMINATION trial has cemented lenalidomide, bortezomib, and dexamethasone (RVd) with stem cell mobilization followed by lenalidomide until progression as the standard of care for newly-diagnosed multiple myeloma.
Citation(s)
- ASCO 2022